GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » Price-to-Owner-Earnings

HAEMATO AG (XTER:HAEK) Price-to-Owner-Earnings : 4.23 (As of May. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG Price-to-Owner-Earnings?

As of today (2024-05-27), HAEMATO AG's share price is €21.40. HAEMATO AG's Owner Earnings per Share (TTM) ended in Dec. 2022 was €5.06. It's Price-to-Owner-Earnings for today is 4.23.


The historical rank and industry rank for HAEMATO AG's Price-to-Owner-Earnings or its related term are showing as below:

XTER:HAEK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.52   Med: 8.06   Max: 71.74
Current: 4.23

During the past 13 years, the highest Price-to-Owner-Earnings of HAEMATO AG was 71.74. The lowest was 3.52. And the median was 8.06.


XTER:HAEK's Price-to-Owner-Earnings is ranked better than
95.22% of 418 companies
in the Drug Manufacturers industry
Industry Median: 27.325 vs XTER:HAEK: 4.23

As of today (2024-05-27), HAEMATO AG's share price is €21.40. HAEMATO AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.84. Therefore, HAEMATO AG's PE Ratio for today is 11.62.

As of today (2024-05-27), HAEMATO AG's share price is €21.40. HAEMATO AG's EPS without NRI for the trailing twelve months (TTM) ended in was €1.28. Therefore, HAEMATO AG's PE Ratio without NRI for today is 16.67.

During the past 13 years, HAEMATO AG's highest PE Ratio without NRI was 27.01. The lowest was 8.07. And the median was 14.58.


HAEMATO AG Price-to-Owner-Earnings Historical Data

The historical data trend for HAEMATO AG's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG Price-to-Owner-Earnings Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.94 10.44 4.56

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.44 - 4.56 -

Competitive Comparison of HAEMATO AG's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's Price-to-Owner-Earnings falls into.



HAEMATO AG Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

HAEMATO AG's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=21.40/5.06
=4.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG  (XTER:HAEK) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


HAEMATO AG Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines